By: Adam Feuerstein | 06/09/14 - 09:22 AM EDT
With Merck (MRK) gobbling up Idenix Pharmaceuticals (IDIX) for $3.9 billion Monday, the hepatitis C takeout speculation shifts to Achillion Pharmaceuticals (ACHN).
Johnson & Johnson (JNJ) and Abbvie (ABBV) were both reportedly interesting in buying Idenix but lost out to Merck, reports CNBC. Achillion shares are up almost 30% to $3.74 Monday as investors bet the losers in the Idenix sweepstakes may move on to the next target.
Using the Idenix premium, an acquisition of Achillion would be considerably cheaper -- less than $1 billion at Friday's closing stock price.
Like Idenix, Achillion has a pipeline of hepatitis C drugs. The most valuable, perhaps, is ACH-3422, a nucleotide NS5B polyermase inhibitor. The conventional thinking is that so-called "nucs" are the linchpin of hepatitis C combination therapy. Gilead Sciences' (GILD) Sovaldi is a nuc and will likely generate $9-10 billion in sales this year. Idenix is developing a nuc, which is probably why Merck acquired the company.
Achillion's nuc is unpartnered, but for how long?
07/28/14 - 12:34 PM EDT
07/28/14 - 10:56 AM EDT
07/28/14 - 09:44 AM EDT
07/25/14 - 11:30 AM EDT
07/24/14 - 09:21 AM EDT
07/28/14 - 14:30 PM EDT
07/28/14 - 12:37 PM EDT
07/27/14 - 16:07 PM EDT
07/26/14 - 13:26 PM EDT
07/25/14 - 11:29 AM EDT
Access the tool that DOMINATES the Russell 2000 and the S&P 500.